Established in 2008, PharmAbcine Inc. is an antibody therapeutics biotech company located in Daejeon, South Korea. We are developing therapeutic antibodies for oncology, immuno-oncology and ophthalmology indications. We generate our antibody pipeline from our proprietary HuPhage library and innovative selection system.
Our lead asset olinvacimab is a tumor angiogenesis inhibitor with a best-in-class potential, and is currently in three clinical studies. Our potentially first-in-class preclinical assets are being prepared for clinical studies in 2022: PMC-309 (anti-VISTA mAb) and PMC-403 (anti-TIE2 mAb).